Literature DB >> 4080444

Alkalosis attenuates hypoxic pulmonary vasoconstriction in neonatal lambs.

R K Lyrene, K A Welch, G Godoy, J B Philips.   

Abstract

Hyperventilation (respiratory alkalosis) is an important treatment for persistent pulmonary hypertension in neonates. The precise way that hyperventilation attenuates hypoxic pulmonary vasoconstriction is unclear. We studied the effect of alkalosis on hypoxia-induced pulmonary vasoconstriction in 13 acutely instrumented, pentobarbital anesthetized, neonatal lambs. We specifically examined the relative effects of a metabolic alkalosis versus a respiratory alkalosis on hypoxic pulmonary vasoconstriction and compared these results to the control response to hypoxia without alkalosis. Hypoxic pulmonary vasoconstriction was significantly milder whenever the animal was alkalotic, regardless of whether the alkalosis was respiratory of metabolic. Thus, the elevated pHa rather than decreased PaCO2 during hyperventilation appears to be the major factor in moderating the response of the pulmonary vessels to acute hypoxia in this neonatal lamb model.

Entities:  

Mesh:

Year:  1985        PMID: 4080444     DOI: 10.1203/00006450-198512000-00009

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  3 in total

1.  Oxygen modulates prostacyclin synthesis in ovine fetal pulmonary arteries by an effect on cyclooxygenase.

Authors:  P W Shaul; W B Campbell; M A Farrar; R R Magness
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

Review 2.  Hypoxic pulmonary vasoconstriction.

Authors:  J T Sylvester; Larissa A Shimoda; Philip I Aaronson; Jeremy P T Ward
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 46.500

3.  THAM reduces CO2-associated increase in pulmonary vascular resistance - an experimental study in lung-injured piglets.

Authors:  Staffan Höstman; João Batista Borges; Fernando Suarez-Sipmann; Kerstin M Ahlgren; Joakim Engström; Göran Hedenstierna; Anders Larsson
Journal:  Crit Care       Date:  2015-09-17       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.